December 11, 2017

Spirosure Makes FDA 510(k) Submission for Clearance to Sell Fenom PRO™ Point-of-Care Breathalyzer in the U.S.

CE mark already in place for portable analyzer that helps patients manage their asthma by measuring nitric oxide (NO) in their exhaled breath, a biomarker foreshadowing airway obstruction


November 2, 2017

NTK Sensor Power Femon PRO

Nagoya, November 2, 2017―NGK SPARK PLUG CO., LTD. (Chairman, President, and CEO: Shinichi Odo, Headquarters: Nagoya, hereafter NTK) is pleased to announce that its sensing unit has been adopted to an exhaled nitric oxide (NO) measuring instrument and will be distributed in Europe starting on November 20, 2017. 


August 3, 2016

SPIROMETRIX RECEIVES CE MARK FOR ITS FENOM PRO™ POINT-OF-CARE BREATHALYZER

Commercialization to start soon for company’s initial product, Fenom PRO™, a point-of-care portable breath analyzer that measures nitric oxide in exhaled breath, a biomarker that foreshadows airway obstruction


JUNE 30, 2016

Spirometrix Raises $17.4 Million Series C Financing

Funding will drive commercialization of the company’s initial product, Fenom PRO™, a point-of-care portable breath analyzer that measures nitric oxide in exhaled breath, a biomarker that foreshadows airway obstruction


FEBURARY 9, 2016


JULY 17, 2015

SPIROMETRIX RECEIVES ISO 13485 CERTIFICATION


NOVEMBER 7, 2014

 

 

 

SPIROMETRIX CLOSES $8.6 MILLION SERIES B FINANCING

Spirometrix announced today the closing of an $8.6 million Series B Preferred Stock financing. The financing was led by biosensor manufacturing partner NGK SPARK PLUG CO., LTD (hereafter NTK), which invested approximately $5 million, and also included current investor Simul Investments. As part of the financing, a member of NTK will join the Board of Directors of Spirometrix.